AstraZeneca Pharma India (506820) Q1 25/26 earnings summary

Executive summary

• Revenue grew 36% year-over-year in Q1 FY25-26, driven by strong performance across therapy areas and strategic execution.

• Four new regulatory approvals in Oncology and Rare Disease segments reinforced leadership and expanded the portfolio.

• Continued focus on science-led innovation and disciplined execution to transform patient outcomes.

Financial highlights

• Total revenue from operations reached ₹5,263.1 million, up from ₹3,875.2 million in Q1 last year.

• Profit before exceptional items and tax was ₹750.6 million, compared to ₹424.0 million year-over-year.

• Profit after exceptional items and tax stood at ₹558.3 million, reversing a loss of ₹117.9 million in the prior year quarter.

• Earnings per share (basic and diluted) were ₹22.33, compared to a loss per share of ₹4.72 in Q1 last year.

Outlook and guidance

• Management remains focused on expanding the portfolio, strengthening partnerships, and ensuring access to breakthrough medicines.

• Strategic execution and regulatory milestones are expected to continue driving growth.